Correct Answer: C. Voriconazole
Voriconazole is the gold-standard first-line agent for invasive pulmonary aspergillosis (IPA), particularly in immunocompromised hosts (neutropenic patients, transplant recipients, advanced HIV). It is a second-generation triazole with superior CNS penetration and broad-spectrum activity against Aspergillus fumigatus, the most common causative species in India. Voriconazole achieves excellent lung tissue concentrations and demonstrates superior clinical outcomes compared to amphotericin B in randomized trials. The EORTC/MSGERC guidelines and Indian mycology consensus recommend voriconazole as first-line therapy for IPA. Its mechanism—inhibition of fungal lanosterol 14α-demethylase (CYP51)—is highly effective against Aspergillus species. Dosing is typically 6 mg/kg IV twice daily for 2 doses, then 4 mg/kg twice daily. Oral bioavailability is excellent (>90%), allowing step-down to oral therapy once clinical improvement occurs. In Indian practice, where IPA is increasingly recognized in diabetic ketoacidosis, hematologic malignancies, and post-COVID immunosuppression, voriconazole remains the preferred agent due to efficacy, tolerability, and availability in most tertiary centers.
Why the other options are wrong
A. Posaconazole — Posaconazole is a second-generation triazole with good activity against Aspergillus, but it is reserved for prophylaxis in high-risk patients or salvage therapy for refractory IPA. It has lower bioavailability and slower onset compared to voriconazole, making it suboptimal for acute invasive disease. NBE may trap students who confuse prophylactic use (where posaconazole is preferred) with treatment of established IPA. B. Itraconazole — Itraconazole is a first-generation triazole with limited CNS penetration and variable bioavailability, particularly in critically ill patients with altered GI absorption. It has inferior efficacy in IPA compared to voriconazole and is not recommended as first-line therapy by international guidelines. It may be used for chronic pulmonary aspergillosis or as step-down oral therapy, but never for acute invasive disease. D. Lyophylised Amphotericin B — While amphotericin B (conventional or liposomal formulation) was historically the standard for IPA, voriconazole has demonstrated superior efficacy and tolerability in head-to-head trials. Amphotericin B is now reserved for voriconazole-intolerant patients, renal impairment, or CNS aspergillosis. Its nephrotoxicity and infusion-related toxicity make it a second-line agent in modern practice.
High-Yield Facts
- Voriconazole is first-line for invasive pulmonary aspergillosis (IPA) in immunocompromised hosts per EORTC/MSGERC and Indian mycology guidelines.
- Voriconazole dosing: 6 mg/kg IV BD × 2 doses, then 4 mg/kg BD; oral bioavailability >90% allows step-down therapy.
- Aspergillus fumigatus is the most common cause of IPA in India; voriconazole achieves superior lung tissue concentrations.
- Posaconazole is reserved for prophylaxis in high-risk patients or salvage therapy; not first-line for acute IPA.
- Amphotericin B is now second-line due to nephrotoxicity; used only if voriconazole contraindicated or CNS involvement.
- Risk factors for IPA in India: neutropenia, hematologic malignancies, post-COVID immunosuppression, advanced HIV, organ transplantation.
Mnemonics
IPA Drug Hierarchy (VPA) Voriconazole (first-line) → Posaconazole (prophylaxis/salvage) → Amphotericin B (refractory/CNS). Use when deciding antifungal for invasive aspergillosis. Triazole Tiers for Aspergillus Second-gen triazoles (voriconazole, posaconazole) beat first-gen (itraconazole) for invasive disease. Voriconazole > posaconazole for acute IPA.
NBE Trap
NBE may pair posaconazole with IPA treatment to trap students who confuse its prophylactic role (where it is preferred) with acute invasive disease management. Similarly, amphotericin B may be offered as a "classic" answer, but modern guidelines have shifted to voriconazole as first-line.
Clinical Pearl
In Indian tertiary centers, IPA is increasingly recognized in post-COVID patients with prolonged immunosuppression and in diabetic ketoacidosis with rhinocerebral extension. Early voriconazole initiation (within 24 hours of diagnosis) significantly improves survival in these high-risk cohorts.
_Reference: Jawetz, Melnick & Adelberg's Medical Microbiology (Ch. Antifungal Agents); EORTC/MSGERC Invasive Fungal Infection Guidelines; Harrison's Principles of Internal Medicine Ch. 205 (Aspergillosis)_